JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kisor, D. F.
Right arrow Articles by Cook, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kisor, D. F.
Right arrow Articles by Cook, D. R.

Anesthesia & Analgesia, Vol 83, 1065-1071, Copyright © 1996 by International Anesthesia Research Society


GENERAL ARTICLES

Importance of the organ-independent elimination of cisatracurium

DF Kisor, VD Schmith, WA Wargin, CA Lien, E Ornstein and DR Cook
Division of Clinical Pharmacology, Glaxo Wellcome Inc., Research Triangle Park, North Carolina 27709, USA.

Cisatracurium, one of 10 isomers of atracurium, undergoes pH and temperature-dependent Hofmann elimination in plasma and tissues. The clearance of cisatracurium due to Hofmann elimination and organ elimination was estimated by applying a nontraditional two-compartment pharmacokinetic model with elimination occurring from both compartments to plasma cisatracurium concentration-time data from 31 healthy adult surgical patients with normal renal and hepatic function. The elimination rate constant from the central compartment, intercompartmental rate constants, and the volume of the central compartment were obtained from the model fit. The elimination rate constant from the peripheral compartment could not be independently estimated in vivo and was therefore fixed to the rate of degradation of cisatracurium in human plasma (pH 7.4 and 37 degrees C) and held constant in the model. Total body clearance, Hofmann clearance, organ clearance, and the volume of distribution at steady-state were derived from the model parameter estimates. Renal clearance was calculated from cisatracurium urinary excretion data from 12 of the 31 patients. Clearance values (mean +/- SD) were 5.20 +/- 0.86, 4.00 +/- 1.04, 1.20 +/- 0.71, and 0.85 +/- 0.32 mL.min-1.kg-1 for total body clearance, Hofmann clearance, organ clearance, and renal clearance, respectively. Hofmann clearance accounted for 77% of total body clearance. Organ clearance was 23% of total body clearance. Renal clearance, a component of organ clearance, was 16% of total body clearance. The organ- independent nature of the elimination of cisatracurium was characterized by a relationship between steady-state volume of distribution and total body clearance. The half-life is an independent variable and is not dependent on the total body clearance nor the steady-state volume of distribution. Hofmann elimination is the predominant pathway for cisatracurium elimination in humans.


This article has been cited by other articles:


Home page
Br J AnaesthHome page
A. A. Dahaba, G. Wang, X. Xu, X. Liu, X. Wu, H. Bornemann, and H. Metzler
Influence of acute normovolaemic haemodilution on the dose-response relationship and time course of action of cisatracurium besylate
Br. J. Anaesth., March 1, 2007; 98(3): 342 - 346.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
K. Imbeault, D. E. Withington, and F. Varin
Pharmacokinetics and Pharmacodynamics of a 0.1 mg/kg Dose of Cisatracurium Besylate in Children During N2O/O2/Propofol Anesthesia.
Anesth. Analg., March 1, 2006; 102(3): 738 - 743.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
A. Richard, F. Girard, D. C. Girard, D. Boudreault, P. Chouinard, R. Moumdjian, A. Bouthilier, M. Ruel, J. Couture, and F. Varin
Cisatracurium-Induced Neuromuscular Blockade Is Affected by Chronic Phenytoin or Carbamazepine Treatment in Neurosurgical Patients
Anesth. Analg., February 1, 2005; 100(2): 538 - 544.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
M. Weindlmayr-Goettel, H. Gilly, and H. G. Kress
Does ester hydrolysis change the in vitro degradation rate of cisatracurium and atracurium?
Br. J. Anaesth., April 1, 2002; 88(4): 555 - 562.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
E. W. Moore and J. M. Hunter
The new neuromuscular blocking agents: do they offer any advantages?
Br. J. Anaesth., December 1, 2001; 87(6): 912 - 925.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
G. Dhonneur, C. Cerf, F. Lagneau, J. Mantz, C. Gillotin, and P. Duvaldestin
The Pharmacokinetics of Cisatracurium in Patients with Acute Respiratory Distress Syndrome
Anesth. Analg., August 1, 2001; 93(2): 400 - 404.
[Abstract] [Full Text] [PDF]


Home page
Canadian J. AnesthesiaHome page
D. R. Miller, C. Wherrett, K. Hull, J. Watson, and S. Legault
Cumulation characteristics of cisatracurium and rocuronium during continuous infusion
Can J Anesth, October 1, 2000; 47(10): 943 - 949.
[Abstract] [PDF]




Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 1996 by the International Anesthesia Research Society.